替格瑞洛对经皮冠状动脉介入术后预后效果的影响

Ticagrelor on Prognosis Efficacy after Percutaneous Coronary Intervention

目的探讨替格瑞洛对急性冠状动脉综合征患者经皮冠状动脉介入术后预后效果的影响。方法选择2014年1月至2015年2月急性冠状动脉综合征患者60例,均接受经皮冠状动脉介入术治疗,按随机数字表法将其分为对照组(氯吡格雷)和观察组(替格瑞洛),各30例。比较两组术前、术后血小板聚集指标及心肌酶谱指标变化情况,以及随访6个月期间心脏不良事件及出血事件发生情况。结果与对照组相比,观察组术后血小板最大聚集率(MPAR)、P2Y12反应单位、肌酸激酶同工酶(CK-MB)、肌钙蛋白(cTnI)水平均明显降低(P<0.05);观察组心脏不良事件发生率显著降低(P<0.05)。结论替格瑞洛能明显减少急性冠状动脉综合征患者经皮冠状动脉介入术后血小板的聚集,降低心脏不良事件发生率,提高患者术后的预后质量。

Objective To study the efficacy of ticagrelor on prognosis for patients with acute coronary syndrome after percutaneous coronary intervention.M ethods 60 patients with acute coronary syndrome treated by percutaneous coronary intervention in the hospital during the period from January 2014 to February 2015 were divided into the control group（clopidogrel） and the observation group（ticagrelor） according to the random number method,30 cases in each group.The index changes of platelet aggregation and myocardial enzyme spectrum on pre- and post- operation,and the incidence of cardiac adverse events and bleeding events during the 6 months follow-up in the two groups were observed.Results Compared with the control group,the maximum platelet aggregation rate（MPAR）and P2Y12 reactivity unit,creatine kinase MB（CK-MB） and troponin（cTnI） were significantly reduced on post- operation in the observation group（P〈0.05）;the incidence of cardiac adverse events were obviously decreased in the observation group（P〈0.05）.Conclusion Ticagrelor can significantly reduce the platelet aggregation after percutaneous coronary intervention for patients with acute coronary syndrome,decrease the incidence of cardiac adverse events,and improve the patients＇ prognosis quality.